Impairment is the recognition that an asset’s carrying value on the balance sheet exceeds the amount the business can recover from it — either through its continued use (value in use) or through its sale (fair value less costs to sell). The higher of these two recovery amounts is the asset’s recoverable amount. When the recoverable amount is less than the carrying value, the difference is the impairment loss — recognised immediately in the income statement, reducing both the asset’s balance sheet value and the period’s reported profit. Under IAS 36, impairment is not optional when indicators are present: finance leaders must actively assess their asset base for indicators of impairment at each reporting date and conduct formal impairment tests when indicators are found.
In the Context of Egypt and the GCC
Several macro events in recent years have created impairment indicators for GCC and Egyptian businesses. Rising interest rates increase the discount rates used in value-in-use calculations, reducing the present value of future cash flows and potentially pushing recoverable amounts below carrying values for assets that were previously unimpaired. EGP devaluation creates impairment risk for Egyptian businesses that have USD-denominated borrowings against EGP-generating assets — if the EGP value of future cash flows is insufficient to recover the USD-denominated carrying value of an asset after devaluation. And in Saudi Arabia, the transformation of certain sectors under Vision 2030 — as domestic demand shifts from legacy products and services to new alternatives — creates obsolescence risk for assets serving declining legacy demand.
The Impairment Assessment Process
A rigorous impairment assessment has three stages. First, the indicator assessment — identifying whether any event or change in circumstance suggests a specific asset or CGU may be impaired: declining revenue, loss of a major customer, a significant decline in market value, evidence of physical damage, or changes in the business environment. Second, the recoverable amount estimation — calculating the value in use using a discounted cash flow model, or obtaining a fair value estimate through market comparison or valuation. Third, the impairment recognition — comparing the recoverable amount to the carrying value and recognising the impairment charge if the carrying value exceeds the recoverable amount. At each stage, the inputs and assumptions must be documented and reviewed — because impairment assessments that are not adequately documented are difficult to defend to auditors or to investors.
What Goes Wrong
The specific impairment failure with the most significant financial consequence is the deferral of impairment recognition — identifying indicators of impairment but concluding that no formal test is required, or performing a formal test but using overly optimistic assumptions that support the carrying value without genuine challenge. When impairment is deferred across multiple periods, the eventual recognition is a large, concentrated P&L charge that creates a significant earnings shock. Progressive recognition — through rigorous indicator assessment and realistic impairment testing at each reporting date — produces smaller, more timely charges that are less disruptive to investor confidence.
How Loop Wise Solutions Encounters This
In EPM health check and financial advisory engagements, we review the client’s impairment testing processes as a standard component — specifically assessing whether discount rates are appropriately calibrated to the risk of each CGU and whether the cash flow projections used in value-in-use calculations are consistent with the financial plan, rather than being separately prepared optimistic projections that are not challenged by the planning process.
